Our findings highlight the benefits of ACMSD inhibition in enhancing hepatic NAD+ levels and enabling genomic protection, underscoring its therapeutic potential in MASLD/MASH. This evidence concerns the gene ACMSD and metabolic dysfunction-associated steatotic liver disease.